Nektar Therapeutics Stock Buy Hold or Sell Recommendation
| NKTR Stock | USD 0.90 0.08 9.76% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Nektar Therapeutics is 'Cautious Hold'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell Nektar Therapeutics within the specified time frame.
Check out Nektar Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide. Note, we conduct extensive research on individual companies such as Nektar and provide practical buy, sell, or hold advice based on investors' constraints. Nektar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Nektar |
Execute Nektar Therapeutics Buy or Sell Advice
The Nektar recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Nektar Therapeutics. Macroaxis does not own or have any residual interests in Nektar Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Nektar Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Inconclusive | Details |
Nektar Therapeutics Trading Alerts and Improvement Suggestions
| Nektar Therapeutics generated a negative expected return over the last 90 days | |
| Nektar Therapeutics has high historical volatility and very poor performance | |
| Nektar Therapeutics has some characteristics of a very speculative penny stock | |
| Nektar Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 90.12 M. Net Loss for the year was (276.06 M) with profit before overhead, payroll, taxes, and interest of 67.74 M. | |
| Nektar Therapeutics currently holds about 546.39 M in cash with (192.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Nektar Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Stock Analysts Upgrades for March 14th |
Nektar Therapeutics Returns Distribution Density
The distribution of Nektar Therapeutics' historical returns is an attempt to chart the uncertainty of Nektar Therapeutics' future price movements. The chart of the probability distribution of Nektar Therapeutics daily returns describes the distribution of returns around its average expected value. We use Nektar Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Nektar Therapeutics returns is essential to provide solid investment advice for Nektar Therapeutics.
| Mean Return | -0.04 | Value At Risk | -8.6 | Potential Upside | 10.11 | Standard Deviation | 5.57 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Nektar Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Nektar Stock Institutional Investors
The Nektar Therapeutics' institutional investors refer to entities that pool money to purchase Nektar Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | State Street Corp | 2024-12-31 | 3.3 M | Altium Capital Management, Lp | 2024-12-31 | 3 M | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 2.6 M | 22nw, Lp | 2024-12-31 | 2.2 M | Monaco Asset Management | 2024-12-31 | 2 M | Ikarian Capital, Llc | 2024-12-31 | 2 M | Deep Track Capital, Lp | 2024-12-31 | 2 M | Ubs O'connor Llc | 2024-12-31 | 1.6 M | Two Sigma Investments Llc | 2024-12-31 | 1.5 M | Blackrock Inc | 2024-12-31 | 16.1 M | Vanguard Group Inc | 2024-12-31 | 12.3 M |
Nektar Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 102.6M | (173.7M) | 63.0M | (53.0M) | (47.7M) | (45.3M) | |
| Free Cash Flow | (320.5M) | (427.6M) | (309.7M) | (193.5M) | (174.1M) | (165.4M) | |
| Depreciation | 14.2M | 14.1M | 13.0M | 7.8M | 9.0M | 16.0M | |
| Other Non Cash Items | (14.4M) | 17.4M | (9.4M) | 62.2M | 56.0M | 58.8M | |
| Capital Expenditures | 7.3M | 15.0M | 5.7M | 865K | 778.5K | 739.6K | |
| Net Income | (444.4M) | (523.8M) | (368.2M) | (276.1M) | (248.5M) | (236.0M) | |
| End Period Cash Flow | 199.0M | 25.2M | 88.2M | 35.3M | 40.6M | 71.6M | |
| Change To Inventory | (2.6M) | (509K) | (3.4M) | 699K | 803.9K | 844.0K | |
| Investments | 503.5M | 217.8M | 365.8M | 162.2M | 186.5M | 195.9M | |
| Change Receivables | (25.5M) | 6.4M | 1.9M | 12.4M | 11.2M | 11.7M | |
| Change To Netincome | 88.5M | 76.0M | 120.1M | 50.7M | 58.3M | 50.1M |
Nektar Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Nektar Therapeutics or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Nektar Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Nektar stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.11 | |
β | Beta against Dow Jones | 1.52 | |
σ | Overall volatility | 5.78 | |
Ir | Information ratio | 0.01 |
Nektar Therapeutics Volatility Alert
Nektar Therapeutics exhibits very low volatility with skewness of 1.17 and kurtosis of 3.25. Nektar Therapeutics is a potential penny stock. Although Nektar Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Nektar Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Nektar instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Nektar Therapeutics Fundamentals Vs Peers
Comparing Nektar Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Nektar Therapeutics' direct or indirect competition across all of the common fundamentals between Nektar Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Nektar Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Nektar Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Nektar Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Nektar Therapeutics to competition |
| Fundamentals | Nektar Therapeutics | Peer Average |
| Return On Equity | -1.24 | -0.31 |
| Return On Asset | -0.23 | -0.14 |
| Profit Margin | (1.21) % | (1.27) % |
| Operating Margin | (0.85) % | (5.51) % |
| Current Valuation | 14.17 M | 16.62 B |
| Shares Outstanding | 184.46 M | 571.82 M |
| Shares Owned By Insiders | 1.27 % | 10.09 % |
| Shares Owned By Institutions | 72.51 % | 39.21 % |
| Number Of Shares Shorted | 7.48 M | 4.71 M |
| Price To Earning | 8.02 X | 28.72 X |
| Price To Book | 3.08 X | 9.51 X |
| Price To Sales | 1.68 X | 11.42 X |
| Revenue | 90.12 M | 9.43 B |
| Gross Profit | 67.74 M | 27.38 B |
| EBITDA | (243.11 M) | 3.9 B |
| Net Income | (276.06 M) | 570.98 M |
| Cash And Equivalents | 546.39 M | 2.7 B |
| Cash Per Share | 2.91 X | 5.01 X |
| Total Debt | 117.78 M | 5.32 B |
| Debt To Equity | 0.33 % | 48.70 % |
| Current Ratio | 7.14 X | 2.16 X |
| Book Value Per Share | 0.29 X | 1.93 K |
| Cash Flow From Operations | (192.61 M) | 971.22 M |
| Short Ratio | 2.26 X | 4.00 X |
| Earnings Per Share | (0.84) X | 3.12 X |
| Price To Earnings To Growth | 3.22 X | 4.89 X |
| Target Price | 4.75 | |
| Beta | 0.66 | -0.15 |
| Market Capitalization | 165.42 M | 19.03 B |
| Total Asset | 398.03 M | 29.47 B |
| Retained Earnings | (3.48 B) | 9.33 B |
| Working Capital | 279.43 M | 1.48 B |
| Current Asset | 350.05 M | 9.34 B |
Note: Disposition of 16560 shares by Mark Wilson of Nektar Therapeutics at 0.89 subject to Rule 16b-3 [view details]
Nektar Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Nektar . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Nektar Therapeutics Buy or Sell Advice
When is the right time to buy or sell Nektar Therapeutics? Buying financial instruments such as Nektar Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Nektar Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Strategy ETFs Thematic Idea Now
Strategy ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Strategy ETFs theme has 1346 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Strategy ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.